metricas
covid
Buscar en
Atención Primaria
Toda la web
Inicio Atención Primaria Riesgo coronario y prescripción en pacientes con hipercolesterolemia en atenciÃ...
Información de la revista
Vol. 25. Núm. 4.
Páginas 209-213 (enero 1999)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 25. Núm. 4.
Páginas 209-213 (enero 1999)
Acceso a texto completo
Riesgo coronario y prescripción en pacientes con hipercolesterolemia en atención primaria
Coronary risk and prescription in primary care patients with hypercholesterolaemia
Visitas
4256
M.V. Bonné Moreno, O. González Löwenberg, E. Charques Velasco, M.M. Alonso Martínez
Autor para correspondencia
y221108003@abonados.cplus.es

Correspondencia: Centro de Salud Mar Báltico. C/ Mar Báltico, 2. 28033 Madrid.
Centro de Salud Mar Báltico. Madrid
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivo

Analizar el riesgo coronario, el tratamiento prescrito y determinar si tras un período se modifica el riesgo coronario (RC) de la población con hipercolesterolemia en atención primaria (AP).

Diseño

Observacional transversal.

Emplazamiento

Población consultante en un equipo de AP urbano de Madrid.

Pacientes

Quinientos ochenta y tres pacientes diagnosticados de hipercolesterolemia de ambos sexos y mayores de 25 años que constan en el registro de morbilidad, seleccionados aleatoriamente.

Mediciones y resultados principales

El RC determinado por el método de Framingham lo consideramos alto si es > 20% a los 10 años. Los pacientes con enfermedad cardiovascular (ECV) inicial tienen prescritos hipolipemiantes la mitad de ellos, con más frecuencia los más jóvenes, presentando un colesterol final de 220 mg/dl de media. Entre los pacientes sin ECV inicial, un 32,5% (28,0-36,7%) tiene un RC > 20% y éstos presentan 4,9% (3,0-8,2) más probabilidad de recibir fármacos que los que lo tienen inferior. La prescripción de hipolipemiantes está explicada en un 68% por el RC elevado y la historia familiar de cardiopatía isquémica. Tras al menos un año de seguimiento, constatamos una reducción en la proporción de pacientes con RC alto (diferencia relativa de proporciones 28,7% [20,4-37,1]).

Conclusión

La mitad de los pacientes con ECV o con un RC elevado sin ECV reciben hipolipemiantes. La mayor parte de la prescripción de fármacos está asociada al RC y en la consulta de AP se consigue disminuir la prevalencia de sujetos con RC elevado.

Palabras clave:
Atención primaria
Hipercolesterolemia
Prescripción
Riesgo coronario
Objective

In patients with hypercholesterolaemia determinate the prevalence of high coronary risk (CR), study the lipid lowering treatment applied and determinate if there is any change in CR after a period of treatment.

Design

Cross-sectional.

Emplacement

Primary care.

Patients

583 patients with hypercholesterolaemia both sex, older than 25 years registred in chronic morbility, aleatoried seleccioned.

Measurement and results

Applying the Framingham coronary multivariate risk method we estimate high CR > 20%. Patients with a previous history of cardiovascular event, were treated in a 50%, more frequently younger subjects, rising 220 mg/dl of final cholesterol level. Patients without any cardiovascular event known, the 32.5% (28.0-36.7%) have a CR > 20%. Subjects with high CR have 4.9 (3.0-8.2) more probability if receiving treatment than the others with lower risk. The lipid-lowering treatment is explained in a 67% because the high CR and the familiy history of coronary event. After at least one year period there is a reduction in those with high CR (diference relative of proportions 28.7% [20.4-37.1]).

El Texto completo está disponible en PDF
Bibliografía
[1.]
T.A. Pearson, P.E. Mcbride, N.H. Miller, S.C. Smith.
Task Force 8: organization of preventive cardiology service.
J Am Coll Cardiol, 27 (1996), pp. 1039-1047
[2.]
C. Asenjo Vázquez, A. Maiques Galán, J. Vilaseca Canals.
Concepto y utilidad del riesgo coronario en el manejo de la hipercolesterolemia.
FMC, 4 (1997), pp. 536-543
[3.]
F. Villar Álvarez, A. Maiques Galán, C. Brotons Cuixart, J. Torcal Laguna, A. Lorenzo Piqueres, J.R. Banegas Banegas, et al.
Grupo de expertos del PAPPS. Prevención de las enfermedades cardiovasculares.
Aten Primaria, 20 (1997), pp. 59-70
[4.]
Summary of the second report of the national cholesterol education program (NCEP).
expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel II).
JAMA, 269 (1993), pp. 3015-3023
[5.]
K.M. Anderson, P.W.F. Wilson, P.M. Odell, W.B. Kannel.
An updated coronary risk profile. A statement for health professionals.
Circulation, 83 (1991), pp. 56-62
[6.]
L.E. Ramsay, I.U. HAQ, P.R. Jackson, W.W. Yeo, D.M. Pickin, J.N. Payne.
Targeting lipid-lowering drug therapy for the primary prevention of coronary disease: an update Sheffield table.
Lancet, 348 (1996), pp. 387-388
[7.]
Scandinavian Simvastatin Survival Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[8.]
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[9.]
The long-term intervention with pravastatin in ischaemic disease (LIPID) study group.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[10.]
J. Shepherd, S.M. Cobbe, I. Ford, C. Isles, A.R. Lorimer, W Macfarlane, et al.
for the West Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[11.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas coronary atherosclerosis prevention study.
JAMA, 279 (1998), pp. 1615-1622
[12.]
I.U. Haq, L.E. Ramsay, D.M. Pickin, W.W. Yeo, P.R. Jackson, J.N. Payne.
Lipid-lowering for prevention of coronary heart disease: what policy now?.
CLIN SCI (Colch), 91 (1996), pp. 399-413
[13.]
M. Johannesson, B. Jönsson, J. Kjekshus, A.G. Olsson, T.R. Pedersen, H. Wedel.
on behalf of the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease.
N Engl J Med, 336 (1997), pp. 322-326
[14.]
P.D.P. Pharoah, W. Hollingworth.
Cost-effectiveness of statins in lowering cholesterol in patients with and without preexisting coronary heart disease: life table method applied to health authority population.
BMJ, 312 (1996), pp. 1443-1447
[15.]
T.A. Jacobson, J.R. Schein, A. Williamson, C.M. Ballantyne.
Maximizing the cost-effectiveness of lipid-lowering therapy.
Arch Intern Med, 158 (1998), pp. 1977-1989
[16.]
J. Caro, W. Klittich, A. McGuire, I. Ford, J. Norrie, a.l. Pettitt D et.
for the West of Scotland Coronary Prevention Study Group. The West of Scotland coronary prevention study: economic benefit analysis of primary with pravastatin.
BMJ, 315 (1997), pp. 1577-1582
[17.]
A. Simon, J.L. Megnien, J. Levenson.
Coronary risk estimation and treatment of hypercholesterolemia.
Circulation, 96 (1997), pp. 2449-2452
[18.]
C. Baxter, R. Jones, L. Corr.
Time trend analysis and variations in prescribing lipid lowering drugs in general practice.
BMJ, 317 (1998), pp. 1134-1135
[19.]
A.H. Anis, G. Carruthers, A.O. Carter, J. Kierulf.
Variability in prescription drug utilization:issues for research.
Can Med Assoc J, 154 (1996), pp. 635-640
[20.]
J. Marion Buen, S. PeiróS, S. Márquez Calderón, R. Meneu de Guillerna.
Variaciones en la práctica médica: importancia, causas e implicaciones.
MED CLIN (Barc), 110 (1998), pp. 382-390
[21.]
INSALUD.
Sistema de Información para centros de atención primaria.
[22.]
K. PyöraläK, G. De Backer, I. Graham, P. Poolewilson, D. Wood.
for the Task Force on the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.
Eur Heart J, 15 (1994), pp. 1300-1331
[23.]
S.M. Grundy.
Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?.
Postgrad Med, 104 (1998), pp. 117-124
[24.]
J.L. Fleiss.
Statistical methods for rates and proportions.
[25.]
S.E. Andrade, A.M. Walker, L.K. Gottleib, N.K. Hollenber, M.A. Testa, G.M. Saperia, et al.
Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflects rates in primary care settings?.
N Engl J Med, 332 (1995), pp. 1125-1131
[26.]
M. Iglesias Rodal, M. Farrús Palou, R. Gimbert Ràfols, I. Montaner Gomis, X. Mundet Tuduri, P. Tomás Santos.
Análisis de los costes de la atención a la hipercolesterolemia en un equipo de atención primaria.
Aten Primaria, 16 (1995), pp. 266-270
[27.]
J. Shepherd, M. Pratt.
Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six european countries in relation to published recommendations.
Cardiology, 87 (1996), pp. 1-5
[28.]
R. Stafford, D. Blumenthal, R. Pasternak.
Variations in cholesterol management practices of U.S. physicians.
J Am Coll Cardiol, 29 (1997), pp. 139-146
[29.]
P.G. Danias, S. O'Mahony, M. Radford, L. Korman, D.I. Silverman.
Serum cholesterol levels are underevaluated and undertreated.
Am J Cardiol, 81 (1998), pp. 1353-1356
[30.]
A. Maiques Galán, M.M. Morales Suárez-Varela, M. Franch Taix, M.D. Alfonso Domènech, P. Moreni-Manzanaro Gómez, J.M. García Torán.
Cálculo del riesgo coronario de los pacientes incluidos en el Programa de Actividades Preventivas y de Promoción de la Salud.
Aten Primaria, 15 (1995), pp. 86-92
[31.]
L.P. Lowe, P. Greenland, K.J. Ruth, A.R. Dyer, R. Stamler, J. Stamler.
Impact of major cardiovascular disease risk factors, particulary in combination, on 22-year mortality in women and men.
Arch Intern Med, 158 (1998), pp. 2007-2014
[32.]
M.A. Martínez González, A. Bueno Cavanillas, M.A. Fernández García, M. García Martín, M. Delgado Rodríguez, R. Gálvez Vargas.
Prevalencia de factores de riesgo cardiovascular en población laboral.
Med Clin (Barc), 105 (1995), pp. 321-326
[33.]
Euroaspire.
A European Society of Cardiology survey of secondary prevention of coronary heart disease:principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to reduce events.
Eur Heart J, 18 (1997), pp. 1569-1582
[34.]
J.P. Frolkis, S.J. Zyzanski, J.M. Schwartz, P.S. Suhan.
Physicians noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines.
Circulation, 98 (1998), pp. 851-855
[35.]
R.N. Lemaitre, C.D. Furberg, A.B. Newman, S.B. Hulley, D.J. Gordon, J.S. Gottdiener, et al.
Time trends in the use of cholesterollowering agents in older adults:the Cardiovascular Health Study.
Arch Intern Med, 158 (1998), pp. 1761-1768
[36.]
E. Delacrétaz, P.G. Michalopoulos, J. Ruiz, H. Saner, B. Meier.
Management of hyperlipidemia after coronary revascularisation: follow up study.
BMJ, 316 (1998), pp. 1499-1500
[37.]
G. Martínez, S. Quiñones, L. Castillo, A. Ramos, E. Avellana, R. Ciurana, et al.
Adecuación del tratamiento farmacológico a las recomendaciones de un protocolo de actuación ante la hipercolesterolemia en atención primaria.
Aten Primaria, 18 (1996), pp. 176-181
[38.]
J. Shepherd.
Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Am J Cardiol, 82 (1998), pp. 57-59
[39.]
P.H. Jones.
Future of lipid-lowering trials: what else do we need to know?.
Am J Cardiol, 82 (1998), pp. 32-38
[40.]
M. Cohen, M. Byrne, B. Levine, T. Gutowski, R. Adelson.
Low rate of treatment hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease.
Circulation, 83 (1991), pp. 1294-1304
[41.]
D. Bramlet, H. King, L. Young, J. Witt, C. Stoukides, A. Kaul.
Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists.
Am J Cardiol, 80 (1997), pp. 39-44
[42.]
C.P. Bradley.
Decision making and prescribing patterns. A literature review.
Family Practice, 8 (1991), pp. 276-287
[43.]
J.A. Garrido Sanjuán, G. Pía Iglesias, J. González Moraleja, P. Sesma.
Indicaciones del tratamiento hipolipemiante en el anciano: experiencia de una unidad de lípidos y revisión de la literatura.
Ann Med Interna (Madrid), 15 (1998), pp. 305-310
[44.]
J. Vilaseca Canals, C. Buxeda Mestre, C. Cámara Contreras, F. Flor Serra, R. Pérez Guinaldo, M. Sánchez Viñas.
¿Tienen riesgo coronario los pacientes que tratamos con fármacos hipolipemiantes?.
Aten Primaria, 20 (1997), pp. 97-103
[45.]
J. Avorn, J. Monette, A. Lacour, R. Bohn, M. Monane, H. Mogun, et al.
Persistence of use lipid-lowering medications. A Cross-National Study.
JAMA, 279 (1998), pp. 1458-1462
[46.]
Standing Medical Advisory Committee.
The use of statins.
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos